Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vincent Rajkumar

Showing results (221-230 of 773) with videos related to

Pageof 78
Sort By:
Otology & Neurotology : Official Publication of the American Otological Society, American Neurotology Society [And] European Academy of Otology and Neurotology|February 14, 2017
Plasmacytoma of the Temporal Bone, a Great Imitator: Report of Seven Cases and Comprehensive Review of the LiteratureAlex D Sweeney, Jacob B Hunter, S Vincent Rajkumar, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|February 3, 2004
Fracture risk in monoclonal gammopathy of undetermined significanceL Joseph Melton, S Vincent Rajkumar, Sundeep Khosla, et al.
Leukemia Research|February 27, 2009
Phase II study of interleukin-12 for treatment of plateau phase multiple myeloma (E1A96): a trial of the Eastern Cooperative Oncology GroupMartha Q Lacy, Susanna Jacobus, Emily A Blood, et al.
British Journal of Haematology|March 6, 2008
Anti-CD20 monoclonal antibody therapy in multiple myelomaPrashant Kapoor, Patricia T Greipp, William G Morice, et al.
European Journal of Haematology|April 2, 2026
Efficacy of CD38-Targeted Therapy in Severe, Multi-Agent Refractory Immune Thrombocytopenia: A Case SeriesParth S Patel, Stefan Farrugia, Jordan Nunnelee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 2009
Building a protocol expressway: the case of Mayo Clinic Cancer CenterTerre A McJoynt, Muhanad A Hirzallah, Daniel V Satele, et al.
American Journal of Hematology|March 18, 2021
Use of endpoints in multiple myeloma randomized controlled trials over the last 15 years: A systematic reviewGhulam Rehman Mohyuddin, Kelly Koehn, Al-Ola Abdallah, et al.
JAMA Oncology|December 13, 2019
Use of Bone-Modifying Agents Among Medicare Beneficiaries With Multiple MyelomaArjun Gupta, Peiqi Wang, Syed Abbas Ali, et al.
Clinical Lymphoma|March 30, 2005
Prognostic factors and predictors of outcome of immunoglobulin M monoclonal gammopathy of undetermined significanceRobert A Kyle, S Vincent Rajkumar, Terry M Therneau, et al.
Mayo Clinic Proceedings|July 13, 2004
Long-term follow-up of 241 patients with monoclonal gammopathy of undetermined significance: the original Mayo Clinic series 25 years laterRobert A Kyle, Terry M Therneau, S Vincent Rajkumar, et al.
Pageof 78

Showing results (221-230 of 773) with videos related to

Sort By:
Pageof 78
Otology & Neurotology : Official Publication of the American Otological Society, American Neurotology Society [And] European Academy of Otology and Neurotology|February 14, 2017
Plasmacytoma of the Temporal Bone, a Great Imitator: Report of Seven Cases and Comprehensive Review of the LiteratureAlex D Sweeney, Jacob B Hunter, S Vincent Rajkumar, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|February 3, 2004
Fracture risk in monoclonal gammopathy of undetermined significanceL Joseph Melton, S Vincent Rajkumar, Sundeep Khosla, et al.
Leukemia Research|February 27, 2009
Phase II study of interleukin-12 for treatment of plateau phase multiple myeloma (E1A96): a trial of the Eastern Cooperative Oncology GroupMartha Q Lacy, Susanna Jacobus, Emily A Blood, et al.
British Journal of Haematology|March 6, 2008
Anti-CD20 monoclonal antibody therapy in multiple myelomaPrashant Kapoor, Patricia T Greipp, William G Morice, et al.
European Journal of Haematology|April 2, 2026
Efficacy of CD38-Targeted Therapy in Severe, Multi-Agent Refractory Immune Thrombocytopenia: A Case SeriesParth S Patel, Stefan Farrugia, Jordan Nunnelee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 2009
Building a protocol expressway: the case of Mayo Clinic Cancer CenterTerre A McJoynt, Muhanad A Hirzallah, Daniel V Satele, et al.
American Journal of Hematology|March 18, 2021
Use of endpoints in multiple myeloma randomized controlled trials over the last 15 years: A systematic reviewGhulam Rehman Mohyuddin, Kelly Koehn, Al-Ola Abdallah, et al.
JAMA Oncology|December 13, 2019
Use of Bone-Modifying Agents Among Medicare Beneficiaries With Multiple MyelomaArjun Gupta, Peiqi Wang, Syed Abbas Ali, et al.
Clinical Lymphoma|March 30, 2005
Prognostic factors and predictors of outcome of immunoglobulin M monoclonal gammopathy of undetermined significanceRobert A Kyle, S Vincent Rajkumar, Terry M Therneau, et al.
Mayo Clinic Proceedings|July 13, 2004
Long-term follow-up of 241 patients with monoclonal gammopathy of undetermined significance: the original Mayo Clinic series 25 years laterRobert A Kyle, Terry M Therneau, S Vincent Rajkumar, et al.
Pageof 78